In addition to imatinib, bevacizumab, as a VEGF inhibitor, has also been found slightly effective in treatment of PTTM with pulmonary hypertension.[7] Other research has shown the limited therapeutic benefit in thrombolysis and traditional chemotherapy.[32–34] ECMO is also considered as a supplemental therapy for bridging of critical ill patients.[35]. The gene discussed is VEGFA; the disease is pulmonary hypertension.